<DOC>
	<DOCNO>NCT01397929</DOCNO>
	<brief_summary>First human , open-label , sequential dose escalation expansion study intravenous BAL101553 adult patient advance solid tumor .</brief_summary>
	<brief_title>An Open-Label Study Intravenous BAL101553 Adult Patients With Solid Tumors</brief_title>
	<detailed_description />
	<criteria>1 . Age ≥ 18 year 2 . Patients one follow advanced recurrent solid tumor type , fail standard therapy effective standard therapy available : colorectal ; gastric cancer gastroesophageal junction ; nonsmall cell lung cancer ; ovarian ( primary peritoneal ) ; pancreatic ( include ampullary ) ; triplenegative breast 3 . Measurable tumor disease ( nonmeasurable ovarian cancer follow CA125 ) 4 . Life expectancy ≥ 12 week 5 . Acceptable organ marrow function baseline ( protocol define laboratory parameter ) 6 . Eastern Cooperative Oncology Group ( ECOG ) performance status ≤ 1 7 . Other protocoldefined inclusion criterion may apply . 1 . Patients receive chemotherapy , radiotherapy , immunotherapy , investigational agent within 4 week prior start study drug recover side effect prior therapy 2 . Symptomatic brain metastasis ( include leptomeningeal disease ) indicative active disease 3 . Peripheral neuropathy ≥ CTCAE v4 grade 2 4 . Uncontrolled intercurrent illness would unduly increase risk toxicity limit compliance study requirement 5 . Women pregnant breastfeeding . Men woman reproductive potential willing apply effective birth control 6 . Systolic blood pressure ≥ 140 mmHg and/or diastolic blood pressure ≥ 90 mmHg observe part screen examination . 7 . Patients treat calcium channel blocker require combination 2 antihypertensive control blood pressure . 8 . Other protocoldefined exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>